Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show ...

A post-hoc analysis of phase 3 trials presented at ACTRIMS Forum 2025 suggests that tolebrutinib may be more effective in MS ...

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...

March 11, 2025 Barclays 27th Annual Global Healthcare Conference, Miami Beach, FL Fireside chat: March 12, 2025, from ...

a non-covalent Bruton's tyrosine kinase inhibitor, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia who have been previously treated with a BTK inhibitor.

Beyond research, Germain concludes the conversation by providing helpful insights into the biggest challenges in lymphoma ...

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

Eli Lilly on Friday said the recommendation covers Jaypirca for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia who have been previously treated with a Bruton's ...

BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...

TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 ...